TICKERNERD
Menu
CRVSCRVSHealthcare · Biotechnology

CRVS Stock Forecast: Corvus Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$13
+0.83% on the day

The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. hold a median 12-month price target of $32 — +139.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$1.1B
Ticker Nerd rank
62 / 100
Median analyst target
$32
Analysts covering
8
Total return, dividends reinvested
1W
+3.5%
1M
−12.2%
YTD
+73.6%
1Y
+226.1%
From 52W high
−47.6%
From 52W low
+223.7%
$4
$26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corvus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
87
Quality
78
Momentum
72
Accruals
58
Growth
48
Size
44
Volatility
41
Revisions
40
Issuance
38

Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (38): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Corvus Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

CRVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26CRVSHigh $42Median $32Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $27Median $32High $42

The green dot is the last close — the median target sits +139.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Apr 2026Goldman SachsInitiatesBuy$40
13 Mar 2026OppenheimerReiteratesOutperform—
22 Jan 2026JefferiesMaintainsBuy—
21 Jan 2026BarclaysMaintainsOverweight—
21 Jan 2026OppenheimerMaintainsOutperform—
20 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Oct 2025BarclaysInitiatesOverweight—
20 May 2025MizuhoMaintainsOutperform—
9 May 2025OppenheimerReiteratesOutperform—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
26 Mar 2025OppenheimerMaintainsOutperform—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
2 Jan 2025HC Wainwright & Co.InitiatesBuy—
13 Nov 2024OppenheimerReiteratesOutperform—
16 Sept 2024Ladenburg ThalmannMaintainsBuy—
7 May 2024OppenheimerMaintainsOutperform—
1 Apr 2024Cantor FitzgeraldReiteratesOverweight—
27 Mar 2024MizuhoMaintainsNeutral—
20 Mar 2024OppenheimerMaintainsOutperform—
7 Sept 2023Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CRVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Corvus Pharmaceuticals, Inc. (CRVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−70.3×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
4.7×

Cheaper than 23% of US stocks

EV / EBITDA
−18.4×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−30.5%

Higher than 27% of US stocks

Return on assets
−19.2%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRVSCorvus Pharmaceuticals, Inc.$1.1B
62
MGTXMeiragtx Holdings plc$1.1B
90
SPTXSeaport Therapeutics, Inc.$1.1B
1
ORICOric Pharmaceuticals, Inc.$1.1B
49
VORVor Biopharma, Inc.$1.1B
23
SVRASavara, Inc.$1.1B
39
LBRXLB Pharmaceuticals, Inc.$1.1B
9
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CRVS news & analysis

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

Corvus Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a business update on August 6, 2026, followed by a conference call and webcast at 4:30 pm ET / 1:30 pm PT.

Why it matters — The announcement signals an upcoming opportunity for CRVS watchers to receive the latest financial performance data and management commentary on the company's progress.

FAQ

Frequently asked questions about CRVS stock

What is the CRVS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Corvus Pharmaceuticals, Inc. have a median 12-month price target of $32, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRVS stock a buy right now?

Of the 8 analysts covering Corvus Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Corvus Pharmaceuticals, Inc. 62 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRVS?

As at 1 Aug 2026, Corvus Pharmaceuticals, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).

Will CRVS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +139.3% from the last close, and Ticker Nerd's factor model ranks Corvus Pharmaceuticals, Inc. 62 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRVS stock forecast for 2030?

No analyst covering Corvus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.

How has CRVS stock performed over the past year?

Corvus Pharmaceuticals, Inc. returned +226.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases.

What is the latest news on CRVS?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026". Corvus Pharmaceuticals announced it will release its second quarter 2026 financial results and provide a business update on August 6, 2026, followed by a conference call and webcast at 4:30 pm ET / 1:30 pm PT.

Company

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing investigational therapies that modulate immune pathways for cancer and immune-mediated diseases. Its primary emphasis is on ITK inhibition through its lead product candidate, soquelitinib, an oral small molecule designed to selectively target interleukin-2-inducible T cell kinase, influencing T cell differentiation and function. This approach aims to address conditions such as peripheral T cell lymphomas, atopic dermatitis, autoimmune lymphoproliferative syndrome, and other inflammatory disorders by promoting Th1 immune responses while suppressing Th2 and Th17 pathways. The company also advances other immune modulators, including ciforadenant, an A2A receptor antagonist for metastatic renal cell cancer, and mupadolimab, a monoclonal antibody for non-small cell lung cancer, often in combination with checkpoint inhibitors. Founded in 2014 and headquartered in South San Francisco, California, Corvus Pharmaceuticals Inc. operates through clinical trials, strategic collaborations like those with Angel Pharmaceuticals for greater China, and preclinical programs targeting adenosine pathways and CXCR2. It plays a specialized role in immuno-oncology and immunology within the biopharmaceutical sector.

CEO Dr. Richard A. Miller M.D. · 37 employees · United States · https://www.corvuspharma.com